Attached files
| file | filename |
|---|---|
| 10-K - FORM 10-K - HAEMONETICS CORP | b80592e10vk.htm |
| EX-21 - EX-21 - HAEMONETICS CORP | b80592exv21.htm |
| EX-10.S - EX-10S - HAEMONETICS CORP | b80592exv10ws.htm |
| EX-32.1 - EX-32.1 - HAEMONETICS CORP | b80592exv32w1.htm |
| EX-31.1 - EX-31.1 - HAEMONETICS CORP | b80592exv31w1.htm |
| EX-31.2 - EX-31.2 - HAEMONETICS CORP | b80592exv31w2.htm |
| EX-10.U - EX-10U - HAEMONETICS CORP | b80592exv10wu.htm |
| EX-23.1 - EX-23.1 - HAEMONETICS CORP | b80592exv23w1.htm |
EXHIBIT 32.2
Certification Pursuant To
18 U.S.C. Section 1350,
As Adopted Pursuant To
Section 906 of the Sarbanes/Oxley Act of 2002
18 U.S.C. Section 1350,
As Adopted Pursuant To
Section 906 of the Sarbanes/Oxley Act of 2002
In connection with the Annual Report of Haemonetics Corporation (the “Company”) on Form 10-K
for the fiscal year ending April 3, 2010 as filed with the Securities and Exchange Commission on
the date hereof (the “Report”), I, Christopher Lindop, Chief Financial Officer and Vice President
Business Development of the Company, certify, pursuant to Section 1350 of Chapter 63 of Title 18,
United States Code, that this Report fully complies with the requirements of Section 13(a) or 15(d)
of the Securities Exchange Act of 1934 and that the information contained in this Report fairly
presents, in all material respects, the financial condition and results of operations of the
Company.
Date: June 1, 2010
| /s/ CHRISTOPHER LINDOP | ||||
| Christopher Lindop, | ||||
| Chief Financial Officer and Vice President Business Development |
||||
A signed original of this written statement required by Section 906, or other document
authenticating, acknowledging, or otherwise adopting the signature that appears in typed form
within the electronic version of this written statement required by Section 906, has been provided
to Haemonetics and will be retained by Haemonetics and furnished to the Securities and Exchange
Commission or its staff upon request.